Hunter Syndrome Treatment Market Size

Hunter Syndrome Treatment Market Insights

Market Overview:

The market for treatments for Hunter syndrome was valued at USD 864.9 million in 2018 and is anticipated to develop at a rate that is both steady and appealing over the coming years. Over the forecast period, the introduction of novel therapies, a strong product pipeline, growing government initiatives, and rising awareness of Hunter syndrome and its treatment options are anticipated to significantly fuel market growth. A uncommon genetic illness called Hunter syndrome, commonly known as mucopolysaccharidosis type II (MPS II), is brought on by a lack of the iduronate-2-sulfatase enzyme. There is currently no long-term treatment for Hunter syndrome. Currently available therapies, such as hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT), concentrate on symptomatic alleviation and the management of problems brought on by the disease's progression.

Hunter Syndrome Treatment Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028

To get more reports on the above market click here to
Get Free Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Biotechnology by segment aggregation, the contribution of the Biotechnology in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

FAQs

The market for Hunter Syndrome Treatment was estimated to be valued at US$ XX Mn in 2021.

The Hunter Syndrome Treatment Market is estimated to grow at a CAGR of XX% by 2028.

The Hunter Syndrome Treatment Market is segmented on the basis of Treatment, Region.

Based on region, the Hunter Syndrome Treatment Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Hunter Syndrome Treatment Market are for the development of such novel therapies are anticipated to be two major factors driving the market growth in the near future. For instance, in June 2019, Denali Therapeutics Inc. received FDA’s Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of the disease., Initiatives undertaken by various organizations for creating awareness regarding the disease diagnosis and its treatment is expected to support market growth over the forecast timeframe. For instance, in May 2018, Shire Plc. in collaboration with the National MPS Society and International MPS Network launched its third #FlyforMPS digital campaign aimed to increase awareness about., Treatment Insights, Based on treatment type, the market is categorized into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2018, the ERT segment accounted for the largest market share and is anticipated to hold onto its dominance over the forecast period. This is attributed to improved sales of Shire Plc’s ELAPRASE and potential for worldwide approval of GC Pharma’s product called Hunterase., Shire Plc’s Elaprase (idursulfase) is the single major drug used for the treatment of Hunter syndrome, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea as of now. These drugs have addressed a significant unmet need. However, the high cost of these drugs is expected to be a major factor hindering their market growth. For instance, Idursulfase (Elaprase) drug costs around USD 3,100 per 6mg/3ml vial., Regional Insights, In 2018, North America dominated the market owing to favorable regulations for orphan drug development, rising awareness among people concerning rare diseases, increased funding for research activities and improved healthcare facilities. Furthermore, the favorable reimbursement policies for expensive drugs such as ELAPRASE in the U.S. have supported its adoption and fueled the regional growth., Asia Pacific region is projected to exhibit a lucrative growth rate over the forecast period. Japan, China, and India are expected to emerge as potential countries for growth, owing to their high unmet needs in the market. Major players are focused on gaining approval for their novel therapies and are penetrating these markets to attain a major share. For instance, in July 2019, CANbridge Pharmaceuticals Inc. filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its novel treatment drug called Hunterase in China. Hunterase (idursulfase beta) is a patented therapy of GC Pharma indicated for the treatment of Hunter syndrome., KEY MARKET SEGMENTS, By Treatment , Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others, By Region, North America, Europe, Asia Pacific, MEA, KEY PLAYERS, Shire Plc. (Takeda Pharmaceutical Company), GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., ArmaGen Inc, Inventiva S.A., Denali Therapeutics Inc., Bioasis Technologies Inc., Esteve.